ClinicalTrials.gg
CompletedNCT04245046Updated Feb 5, 2020

Drug-drug-interaction Study of Candesartan, Amlodipine and Atorvastatin

A Phase 1 interventional study of Candesartan, Amlodipine, Atorvastatin in Healthy Volunteers, sponsored by Midas Pharma GmbH. Completed at 1 site in Jordan. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Midas Pharma GmbH · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jan 2019, registered Jan 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

Study to determine the potential pharmacokinetic interaction of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate and amlodipine as amlodipine besilate at steady state after a multiple oral administration and to monitor the safety of the co-administration of these drugs. This study aims to determine if the steady state study pharmacokinetic parameters of any of the given drugs and the tolerability is altered when administered concomitantly.

Read the detailed description

This study was an open-label, comparative, multiple-dose, fixed sequence steady state trial to compare the pharmacokinetic of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate given as a multiple dose under fasting conditions in the absence and presence of each other.

Bioanalysis of candesartan, atorvastatin and amlodipine is performed by LC/MS/MS method.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Candesartan
  • Amlodipine
  • Atorvastatin
  • drug interaction
  • multiple-dose
  • pharmacokinetic
03

In context

Lead sponsor

Midas Pharma GmbH is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male Caucasian, aged 18 to 50 years, inclusive.
  • (BMI) range within 18.5 - 30.0 Kg/m2.
  • Physically and mentally healthy as judged by means of medical and standard laboratory examinations. Medical demographics performed not longer than two weeks before the initiation of the clinical study with significant deviations from the normal ranges.
  • Standard assessment is normal
  • given in written form according to chapter 5.3 of the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to the drugs under investigation or any ingredients or any other related drugs.
  • Participation in a relative bioavailability study or in a clinical study within the last 80 days before first study drug administration or blood donation
  • Presence of any results from laboratory tests, vital sign assessment and as judged by the investigator. Laboratory tests are performed not longer than two weeks before the initiation of the clinical study.
  • Results of CPK or liver or kidney function tests which are outside the reference range.
  • test lower than 13.3 g/dl.
  • Positive serologic findings
  • History of drug or alcohol abuse.
  • Subject is a heavy smoker.
  • Subject has a history of significant asthma, peptic or gastric ulcer, sinusitis, pharyngitis, renal disorder (impaired renal function), hepatic disorder (impaired hepatic function), cardiovascular disorder, neurological disease such as epilepsy, haematological disorders or diabetes, psychiatric, dermatologic or immunological disorders.
  • Subject having at screening examination a sitting blood pressure of less than 110/70 mm Hg or more than or equal to 140/90 mm Hg.
  • Subjects who are known or suspected: not to comply with the study directives, not to be reliable or trustworthy, not to be capable of understanding and evaluating the information given to them as part of the formal information policy (), in particular regarding the risks and discomfort to which they would agree to be exposed, to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the unpleasantness they may be involved in.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Treatment A-B-C-ABC

    The demographic characteristics of the 18 male subjects were as follows: * Age: 18-49 years * Weight: 55-105 kg * Height: 163-188 cm * BMI 18.5-29.9 kg/m²

    Drug: Candesartan, Amlodipine, Atorvastatin

Interventions

  • DrugCandesartan, Amlodipine, Atorvastatin

    Drug pages: Candesartan · Amlodipine · Atorvastatin

    compare the pharmacokinetic of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate, amlodipine as amlodipine besilate from reference products given as a multiple dose

06

What researchers measure

Primary outcomes

  1. Maximum Plasma concentration at steady state (Cmaxss)

    Maximum plasma concentration, it is read directly from the raw data

    Time frame: up to 24 hours post-administration at steady state

  2. Area under the Plasma concentration curve (AUC0-t)

    Area under the plasma concentration curve from time 0 to the last measured (AUC0-t)

    Time frame: up to 24 hours post-administration at steady state

Secondary outcomes

  1. Safety measurement (Adverse Events)

    All observed or volunteered safety events regardless of treatment group or suspected causal relationship to the investigational product(s) will be reported during study.

    Time frame: complete study, Day 1 until Day 31 (Follow-up)

  2. Time until Cmaxss is reached (tmaxss)

    Time until Cmax is reached, it is read directly from the observed concentrations

    Time frame: up to 24 hours post-administration at steady state

07

Study locations

1 site
  • International Pharmaceutical Research Center
    Amman, Jordan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Feb 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2020
First posted
Jan 28, 2020
StartActual
Jan 18, 2019
Primary completionActual
Feb 18, 2019
CompletionActual
Feb 18, 2019
Last update
Feb 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04245046
Lead sponsor
Midas Pharma GmbH
Responsible party
Sponsor
First posted
Jan 28, 2020
Start date
Jan 18, 2019
Primary completion
Feb 18, 2019
Completion
Feb 18, 2019
Last update
Feb 5, 2020

Study contacts

Mohammed Bader
study director · International Pharmaceutical Research Center, Jordan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Candesartan · Amlodipine · Atorvastatin

Start the discussion